Stock Update (NASDAQ:REGN): Regeneron Genetics Center Publication in New England Journal of Medicine Links ANGPTL4 Inhibition and Risk of Coronary Artery Disease

[PR Newswire] – TARRYTOWN, N.Y., March 2, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (REGN), working in collaboration with Geisinger Health System, today announced that the New England Journal of Medicine has published a paper showing that inactivating mutations of the angiopoeitin-like 4 (ANGPTL4) gene are associated with a significantly reduced risk of coronary artery disease (CAD) in humans. “This is the first of what we hope will be many notable peer-reviewed publications with our collaborators, and one example of how the Regeneron Genetics Center and Geisinger link genetic mutations with real-world health outcomes to make actionable discoveries,” said Alan Shuldiner, M.D., a lead author of the publication and Vice President and Co-Head of the Regeneron Genetics Center LLC (RGC), a wholly-owned subsidiary of Regeneron. Read more on this. Regeneron Pharmaceuticals, Inc. (REGN) , with a current value of $42.68B, began trading this morning at $410.00. Today’s price range has been between $405.26 and $419.00 per share and has traded between $350.26 and $605.93 over the past 12 months. Priced at 35.58x this year’s forecasted earnings, REGN shares are relatively expensive compared to the industry’s -0.27x forward p/e ratio. In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $2.64 per share, which would be $0.24 worse than the year-ago quarter and a $0.91 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $11.53, which would be a $0.54 setback when compared to the last year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $1.18 Billion. If reported, that would be a 35.69% increase over the year-ago quarter. More recently, Citigroup Initiated REGN at Buy (Feb 25, 2016). Previously, Chardan Capital Markets upgraded REGN from Sell to Neutral. Investors should keep in mind is that the average price target is $509.91, which is 24.37% above where the stock opened this morning. See more in (NASDAQ:REGN) Similar Articles: Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron Announces Upcoming 2016 Investor Conference Presentation Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia